5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock soared 45% in after-hours trading Wednesday following the company’s announcement of positive topline results from its Phase 2 study of VTX3232 in patients with obesity and cardiovascular risk factors.
The San Diego-based biopharmaceutical company reported that VTX3232, an oral once-daily NLRP3 inhibitor, demonstrated significant reductions in key cardiovascular risk markers. In the modified analysis set, patients treated with VTX3232 monotherapy showed a 78% reduction in high-sensitivity C-reactive protein (hsCRP) at week 12 compared to a 3% increase in the placebo group.
The drug also lowered interleukin-6 (IL-6) levels below the threshold for cardiovascular risk and achieved statistically significant reductions in lipoprotein(a), fibrinogen, and erythrocyte sedimentation rate. Additionally, the study showed VTX3232 reduced liver inflammation independent of liver fat content.
When combined with semaglutide, VTX3232 provided additional anti-inflammatory benefits beyond what semaglutide achieved alone. However, the company noted that VTX3232 did not affect weight loss either as a monotherapy or as an add-on to semaglutide.
"The robust CRP-lowering possible with novel agents such as NLRP3 inhibitors offers new options for anti-inflammatory therapies to treat atherosclerosis and prevent its complications that add to the established benefits of cholesterol-lowering therapies," said Peter Libby, MD, Cardiovascular Specialist at Mass General Brigham Heart & Vascular Institute and immediate past president of the International Atherosclerosis Society.
Safety data from the 175-participant study showed VTX3232 was well-tolerated, with adverse event rates comparable to placebo throughout the 12-week treatment period.
The company plans to present additional data from the study at upcoming medical conferences and will provide updates on future development plans for VTX3232 in cardiovascular disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.